Thiazolidinediones for initial treatment of type 2 diabetes?
Thiazolidinediones for initial treatment of type 2 diabetes?
复制标题
噻唑烷二酮类药物用于2型糖尿病的初始治疗？
DOI：
10.1056/nejme068264
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
D. Nathan
中科院分区：
文献类型：
--
作者：
D. Nathan
肥胖症和2型糖尿病这对孪生流行病已经引发了一场公共卫生危机。在美国，估计每年有150万新发糖尿病病例，1而预计的微血管和心血管并发症2--已经是西方世界失明、肾衰竭和截肢的最大原因，也是心脏病的重要促成因素--很可能成为本千年可预防疾病和过早死亡的主要原因。这一流行病的严重性反映在以证据为基础的努力，以遏制它。
The twin epidemics of obesity and type 2 diabetes mellitus have spawned a public health crisis. In the United States, an estimated 1.5 million new cases of diabetes occur every year,1 and the projected microvascular and cardiovascular complications2 — already the greatest cause of blindness, kidney failure, and amputations in the Western world, and a substantial contributing factor in heart disease — are likely to become the major cause of preventable disease and premature death in this millennium. The gravity of this epidemic is reflected by evidence-based efforts to stem it.3,4 Moreover, in the United States, approval of five . . .